Showing results (131-140 of 155) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung CancerSolange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2025
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER StudyAntonio Calles, Alejandro Navarro, Bernard Gaston Doger de Speville Uribe, et al.Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.Nature Medicine|February 6, 2024
MYC targeting by OMO-103 in solid tumors: a phase 1 trialElena Garralda, Marie-Eve Beaulieu, Víctor Moreno, et al.Science Translational Medicine|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumorsIgnacio Melero, Tamara Tanos, Mariana Bustamante, et al.The Lancet. Oncology|July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trialRoy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.Pageof 16